In the last trading session, 0.83 million Outlook Therapeutics Inc (NASDAQ:OTLK) shares changed hands as the company’s beta touched 0.00. With the company’s per share price at $8.51 changed hands at -$0.12 or -1.39% during last session, the market valuation stood at $110.72M. OTLK’s last price was a discount, traded about -377.09% off its 52-week high of $40.60. The share price had its 52-week low at $4.00, which suggests the last value was 53.0% up since then. When we look at Outlook Therapeutics Inc’s average trading volume, we note the 10-day average is 2.55 million shares, with the 3-month average coming to 506.68K.
Outlook Therapeutics Inc (NASDAQ:OTLK) trade information
Instantly OTLK was in red as seen at the end of in last trading. With action 9.31%, the performance over the past five days has been green. The drop to weekly highs of 11.72 subtracted -1.39% to the stock’s daily price. The company’s shares are showing year-to-date upside of 7.99%, with the 5-day performance at 9.31% in the green. However, in the 30-day time frame, Outlook Therapeutics Inc (NASDAQ:OTLK) is -2.99% down. Looking at the short shares, we see there were 0.58 million shares sold at short interest cover period of 7.6 days.
Outlook Therapeutics Inc (OTLK) estimates and forecasts
Data shows that the Outlook Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 103.69% over the past 6 months, a 36.67% in annual growth rate that is considerably higher than the industry average of 12.20%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Outlook Therapeutics Inc will fall -41.70%, while the growth in revenue is estimated to hit 46.90% for the next quarter.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 52.49%. The 2024 estimates are for Outlook Therapeutics Inc earnings to increase by 29.28%.
OTLK Dividends
Outlook Therapeutics Inc is expected to release its next quarterly earnings report between May 13 and May 17.
Outlook Therapeutics Inc (NASDAQ:OTLK)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 36.81% of Outlook Therapeutics Inc shares while 6.88% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 10.89%. There are 6.88% institutions holding the Outlook Therapeutics Inc stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 3.54% of the shares, roughly 9.22 million OTLK shares worth $16.04 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 2.36% or 6.15 million shares worth $10.7 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.61 million shares estimated at $6.28 million under it, the former controlled 1.39% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.37% of the shares, roughly 3.58 million shares worth around $0.82 million.
